Page last updated: 2024-12-06

safrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

safrazine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID34042
CHEMBL ID3301845
SCHEMBL ID437129
MeSH IDM0060851

Synonyms (31)

Synonym
(3-(1,3-benzodioxol-5-yl)-1-methylpropyl)hydrazine
brn 1376116
hydrazine, (3-(1,3-benzodioxol-5-yl)-1-methylpropyl)-
saphrazine
safrasin
safrazine
hydrazine, (1-methyl-3-(3,4-(methylenedioxy)phenyl)propyl)-
AKOS000149833
4-(1,3-benzodioxol-5-yl)butan-2-ylhydrazine
unii-f5g0p5378c
f5g0p5378c ,
33419-68-0
858830-96-3
1-[4-(2h-1,3-benzodioxol-5-yl)butan-2-yl]hydrazine
.beta.-piperonylisopropylhydrazine
(+/-)-saphrazine
hydrazine, (1-methyl-3-(3,4-(methylenedioxy)phenyl)propyl)
saphrazine, (+/-)-
safrazine [who-dd]
CHEMBL3301845
SCHEMBL437129
DB09253
safra
DTXSID60860006
(4-(benzo[d][1,3]dioxol-5-yl)butan-2-yl)hydrazine
D87580
[4-(2h-1,3-benzodioxol-5-yl)butan-2-yl]hydrazine
EN300-204750
[4-(1,3-dioxaindan-5-yl)butan-2-yl]hydrazine
CS-0613909
HY-148159

Research Excerpts

Actions

ExcerptReferenceRelevance
"Safrazine induced the increase of PEA without any beneficial effect on the depressive symptoms."( Increase in urinary beta-phenylethylamine preceding the switch from mania to depression: a "rapid cycler".
Kaneno, S; Maruyama, Y; Nankai, M; Semba, J; Takahashi, R; Watanabe, A, 1988
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (88.89)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.52 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies3 (30.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (70.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]